KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Amneal Pharmaceuticals (AMRX) Beginning Cash Balance (2018 - 2024)

Amneal Pharmaceuticals has reported Beginning Cash Balance over the past 3 years, most recently at $32.7 million for Q3 2024.

For Q3 2024, Beginning Cash Balance changed N/A year-over-year to $32.7 million; the TTM value through Dec 2025 reached $32.7 million, changed 0.0%, while the annual FY2024 figure was $44.2 million, N/A changed from the prior year.
Beginning Cash Balance for Q3 2024 was $32.7 million at Amneal Pharmaceuticals, up from $1.0 million in the prior quarter.
Over five years, Beginning Cash Balance peaked at $32.7 million in Q3 2024 and troughed at $1.0 million in Q1 2021.